Management of acute variceal bleeding using hemostatic powder

Bibliographic Information
Authors: Ibrahim M.; El-Mikkawy A.; Abdalla H.; Mostafa I.; Devière J.
Journal: United European Gastroenterology Journal
Publisher: SAGE Publications Ltd
Publication Date: June 2015
Volume / Issue: Volume 3 / Issue 3
Pages: 277–283
ISSN: 20506406
Scopus: View on Scopus
Document Type: Article
Access: All Open Access; Bronze Open Access; Green Open Access
Authors and Affiliations
Ibrahim M., Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium, Department of Gastroenterology and Hepatology, Theodor Bilharz Research Institute, Cairo, Egypt; El-Mikkawy A., Department of Gastroenterology and Hepatology, Theodor Bilharz Research Institute, Cairo, Egypt; Abdalla H., Department of Gastroenterology and Hepatology, Theodor Bilharz Research Institute, Cairo, Egypt; Mostafa I., Department of Gastroenterology and Hepatology, Theodor Bilharz Research Institute, Cairo, Egypt; Devière J., Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
Abstract
Background and objectives: This study aimed to test the safety and efficacy of Hemospray® for emergency control of acute variceal bleeding (AVB) due to portal hypertension in cirrhotic patients. Patients and methods: This single-arm, prospective trial, conducted at two hospitals in Belgium and Egypt, included patients admitted to the emergency room with hematemesis and/or melena and known or suspected liver cirrhosis. All patients received urgent hemodynamic stabilization, octreotide (50 mcg bolus then 25 mcg/hour for 24 hours) and intravenous ceftriaxone (lg/hour). Endoscopy to confirm AVB and Hemospray® application (if indicated) was performed within six hours of admission. Patients were kept under observation for 24 hours and underwent second endoscopy and definitive therapy (band ligation and/or cyanoacrylate injection in cases of gastric varices) the next day. Results: Thirty-eight patients were admitted for suspected AVB, and 30 of these had confirmed AVB (70% male; mean age 59.5 years (range, 32.0-73 years)). Child-Pugh class C liver disease was present in 53.4%. Esophageal varices were observed in 83.4% of patients, gastric varices in 10%, and duodenal varices in 6.6%. Spurting bleeding at the time of endoscopy was observed in 43.4%. One patient developed hematemesis six hours after Hemospray® application and underwent emergency endoscopic band ligation. No major adverse events or mortalities were observed during 15-day follow-up. Conclusion: Hemospray® application was safe and effective at short-term follow-up for emergency treatment of AVB in cirrhotic patients. © Author(s) 2015.
Keywords
Hemostatic powder; Portal hypertension; Variceal bleeding; ceftriaxone; cyanoacrylate; octreotide; acute variceal bleeding; adult; aged; Article; bleeding; Child Pugh score; clinical article; endoscopy; female; hematemesis; hemospray; human; liver cirrhosis; male; melena; powder; priority journal; prospective study
Citation Information
Scopus Citations: 49
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
